Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Breast Cancer Reports
Published in: Current Breast Cancer Reports 3/2020

01-09-2020 | Breast Cancer | Breast Cancer Disparities (LA Newman, Section Editor)

Disparities in Genetic Testing and Care Among Black Women with Hereditary Breast Cancer

Authors: Sonya Reid, Sydney Cadiz, Tuya Pal

Published in: Current Breast Cancer Reports | Issue 3/2020

Login to get access

Abstract

Purpose of Review

Despite a steady improvement in breast cancer survival rates over the past several decades, mortality disparities remain among Black women, who have a 42% higher death rate compared to non-Hispanic white (NHW) women. Hereditary breast cancer (HBC) accounts for 5–10% of all breast cancer cases, the majority of which are due to the BRCA1 and BRCA2 (BRCA) genes. Despite the availability of BRCA testing for over 25 years, there remain disproportionately lower rates of genetic testing among Blacks compared to NHW due to a multitude of factors. The intent of this review is to discuss racial disparities focused on HBC across diverse populations and review the existing gaps to be addressed when delivering gene-based care.

Recent Findings

The factors contributing to the racial survival disparity are undoubtedly complex and likely an interplay between tumor biology, genomics, patterns of care, and socioeconomic factors. Advances in genomic technologies that now allow for full characterization of germline DNA sequencing are integral in defining the complex and multifactorial cause of breast cancer and may help to explain the existing racial survival disparities.

Summary

Identification of inherited cancer risk may lead to cancer prevention, early cancer detection, treatment guidance, and ultimately has great potential to improve outcomes. Consequently, advances in HBC diagnosis and treatment without widespread implementation have the potential to further widen the existing breast cancer mortality gap between Black and NHW women.
Literature
1.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRef
2.
Davis MB, Newman LA. Breast cancer disparities: how can we leverage genomics to improve outcomes? Surg Oncol Clin N Am. 2018;27(1):217–34.PubMed
3.
Huo D, Hu H, Rhie SK, Gamazon ER, Cherniack AD, Liu J, et al. Comparison of breast cancer molecular features and survival by African and European ancestry in the cancer genome atlas. JAMA Oncol. 2017;3(12):1654–62.PubMedPubMedCentral
4.
5.
Newman LA, Bunner S, Carolin K, Bouwman D, Kosir MA, White M, et al. Ethnicity related differences in the survival of young breast carcinoma patients. Cancer. 2002;95(1):21–7.PubMed
6.
Simon MS, Petrucelli N. Hereditary breast and ovarian cancer syndrome : the impact of race on uptake of genetic counseling and testing. Methods Mol Biol. 2009;471:487–500.PubMed
7.
McCarthy AM, Yang J, Armstrong K. Increasing disparities in breast cancer mortality from 1979 to 2010 for US black women aged 20 to 49 years. Am J Public Health. 2015;105 (3):S446–S448.
8.
Aizer AA, Wilhite TJ, Chen MH, Graham PL, Choueiri TK, Hoffman KE, et al. Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. Cancer. 2014;120(10):1532–9.PubMed
9.
DeSantis CE, Siegel RL, Sauer AG, Miller KD, Fedewa SA, Alcaraz KI, et al. Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities. CA Cancer J Clin. 2016;66:290–308.PubMed
10.
Daly B, Olopade OI. A perfect storm: how tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change. CA Cancer J Clin. 2015;65(3):221–38.PubMed
11.
Kroenke CH, Sweeney C, Kwan ML, Quesenberry CP, Weltzien EK, Habel LA, et al. Race and breast cancer survival by intrinsic subtype based on PAM50 gene expression. Breast Cancer Res Treat. 2014;144(3):689–99.PubMedPubMedCentral
12.
Jiagge E, Chitale D, Newman LA. Triple-negative breast cancer, stem cells, and African ancestry. Am J Pathol. 2018;188(2):271–9.PubMed
13.
Society AC. Breast Cancer Facts & Figures 2019-2020. Atlanta: American Cancer society, Inc. 2019.
14.
Walsh SM, Zabor EC, Stempel M, Morrow M, Gemignani ML. Does race predict survival for women with invasive breast cancer? Cancer. 2019;125(18):3139–46.PubMed
15.
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA. 2006;295(21):2492–502.PubMed
16.
Lund MJ, Butler EN, Bumpers HL, Okoli J, Rizzo M, Hatchett N, et al. High prevalence of triple-negative tumors in an urban cancer center. Cancer. 2008;113(3):608–15.PubMed
17.
Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prevent. 2007;16(3):439–43.
18.
Olopade OI, Ikpatt FO, Dignam JJ, Khramtsov A, Tetriakova M, Grushko T, et al. Intrinsic gene expression subtypes correlated with grade and morphometric parameters reveal a high proportion of aggressive basal-like tumors among black women of African ancestry. J Clin Oncol. 2004;22(14S):9509.
19.
Aziz H, Hussain F, Sohn C, Mediavillo R, Saitta A, Hussain A, et al. Early onset of breast carcinoma in African American women with poor prognostic factors. Am J Clin Oncol. 1999;22(5):436–40.PubMed
20.
Newman LA. Breast cancer in African-American women. Oncologist. 2005;10(1):1–14.PubMed
21.
22.
Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003;95(19):1482–5.PubMed
23.
Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14):8418–23.PubMedPubMedCentral
24.
Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkas K, Roberts J, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371(6):497–506.PubMedPubMedCentral
25.
Cybulski C, Kluzniak W, Huzarski T, Wokolorczyk D, Kashyap A, Jakubowska A, et al. Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. Lancet Oncol. 2015;16(6):638–44.PubMed
26.
Young SR, Pilarski RT, Donenberg T, Shapiro C, Hammond LS, Miller J, et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer. 2009;9:86.PubMedPubMedCentral
27.
Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011;17(5):1082–9.PubMedPubMedCentral
28.
Vig HS, Wang C. The evolution of personalized cancer genetic counseling in the era of personalized medicine. Familial Cancer. 2012;11(3):539–44.PubMedPubMedCentral
29.
Pal T, Bonner D, Cragun D, Monteiro AN, Phelan C, Servais L, et al. A high frequency of BRCA mutations in young black women with breast cancer residing in Florida. Cancer. 2015;121(23):4173–80.PubMedPubMedCentral
30.
Felix GES, Zheng Y, Olopade OI. Mutations in context: implications of BRCA testing in diverse populations. Familial Cancer. 2018;17(4):471–83.PubMedPubMedCentral
31.
Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62(3):676–89.PubMedPubMedCentral
32.
Ellsworth RE, Decewicz DJ, Shriver CD, Ellsworth DL. Breast cancer in the personal genomics era. Curr Genomics. 11(3):146–61.
33.
34.
Fackenthal JD, Zhang J, Zhang B, Zheng Y, Hagos F, Burrill DR, et al. High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients. Int J Cancer. 2012;131(5):1114–23.PubMed
35.
Zheng Y, Walsh T, Gulsuner S, Casadei S, Lee MK, Ogundiran TO, et al. Inherited breast cancer in Nigerian women. J Clin Oncol. 2018;36(28):2820–5.PubMedPubMedCentral
36.
Adedokun B, Zheng Y, Ndom P, Gakwaya A, Makumbi T, Zhou AY, et al. Prevalence of inherited mutations in breast cancer predisposition genes among women in Uganda and Cameroon. Cancer Epidemiol Biomarkers Prev. 2020;29(2):359.PubMed
37.
Donenberg T, Lunn J, Curling D, Turnquest T, Krill-Jackson E, Royer R, et al. A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas. Breast Cancer Res Treat. 2011;125(2):591–6.PubMed
38.
Akbari MR, Donenberg T, Lunn J, Curling D, Turnquest T, Krill-Jackson E, et al. The spectrum of BRCA1 and BRCA2 mutations in breast cancer patients in the Bahamas. Clin Genet. 2014;85(1):64–7.PubMed
39.
Donenberg T, Ahmed H, Royer R, Zhang S, Narod SA, George S, et al. A survey of BRCA1, BRCA2, and PALB2 mutations in women with breast cancer in Trinidad and Tobago. Breast Cancer Res Treat. 2016;159(1):131–8.PubMed
40.
•• Kurian AW, Ward KC, Hamilton AS, Deapen DM, Abrahamse P, Bondarenko I, et al. Uptake, results, and outcomes of germline multiple-gene sequencing after diagnosis of breast cancer. JAMA Oncol. 2018;4(8):1066–72 This study found a higher prevalence of variant of uncertain significance (VUS) results in the era of multi-gene sequencing, especially in minority populations. PubMedPubMedCentral
41.
Cragun D, Weidner A, Lewis C, Bonner D, Kim J, Vadaparampil ST, et al. Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors. Cancer. 2017;123(13):2497–505.PubMedPubMedCentral
42.
Yedjou CG, Sims JN, Miele L, Noubissi F, Lowe L, Fonseca DD, et al. Health and racial disparity in breast cancer. In: Ahmad A, editor. Breast cancer metastasis and drug resistance: challenges and progress. Cham: Springer International Publishing; 2019. p. 31–49.
43.
Willoughby A, Andreassen PR, Toland AE. Genetic testing to guide risk-stratified screens for breast cancer. J Pers Med. 2019;9(1):15.PubMedCentral
44.
Kapoor PM, Lindström S, Behrens S, Wang X, Michailidou K, Bolla MK, et al. Assessment of interactions between 205 breast cancer susceptibility loci and 13 established risk factors in relation to breast cancer risk, in the Breast Cancer Association Consortium. Int J Epidemiol. 2020;49(1):216–232.
45.
•• Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat Genet. 2019;51(4):584–91 This review highlights the overrepresentation of European ancestry in genome wide association studies (GWAS). PubMedPubMedCentral
46.
Martin AR, Gignoux CR, Walters RK, Wojcik GL, Neale BM, Gravel S, et al. Human demographic history impacts genetic risk prediction across diverse populations. Am J Hum Genet. 2017;100(4):635–49.PubMedPubMedCentral
47.
Petrovski S, Goldstein DB. Unequal representation of genetic variation across ancestry groups creates healthcare inequality in the application of precision medicine. Genome Biol. 2016;17(1):157.PubMedPubMedCentral
48.
Yadav S, Couch FJ. Germline genetic testing for breast cancer risk: the past, present, and future. Am Soc Clin Oncol Edu Book. 2019;39:61–74.
49.
Metcalfe K, Gershman S, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, et al. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2011;104(9):1384–92.PubMedPubMedCentral
50.
Pierce LJ, Phillips K-A, Griffith KA, Buys S, Gaffney DK, Moran MS, et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat. 2010;121(2):389–98.PubMedPubMedCentral
51.
Menes TS, Terry MB, Goldgar D, Andrulis IL, Knight JA, John EM, et al. Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry. Breast Cancer Res Treat. 2015;151(3):653–60.PubMedPubMedCentral
52.
Malone KE, Begg CB, Haile RW, Borg A, Concannon P, Tellhed L, et al. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol. 2010;28(14):2404–10.PubMedPubMedCentral
53.
54.
Drohan B, Roche CA, Cusack JC Jr, Hughes KS. Hereditary breast and ovarian cancer and other hereditary syndromes: using technology to identify carriers. Ann Surg Oncol. 2012;19(6):1732–7.PubMed
55.
Hall MJ, Reid JE, Burbidge LA, Pruss D, Deffenbaugh AM, Frye C, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer. 2009;115(10):2222–33.PubMedPubMedCentral
56.
Wood ME, Kadlubek P, Pham TH, Wollins DS, Lu KH, Weitzel JN, et al. Quality of cancer family history and referral for genetic counseling and testing among oncology practices: a pilot test of quality measures as part of the American Society of Clinical Oncology Quality Oncology Practice Initiative. J Clin Oncol. 2014;32(8):824–9.PubMedPubMedCentral
57.
Armstrong K, Micco E, Carney A, Stopfer J, Putt M. Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA. 2005;293(14):1729–36.PubMed
58.
Levy DE, Byfield SD, Comstock CB, Garber JE, Syngal S, Crown WH, et al. Underutilization of BRCA1/2 testing to guide breast cancer treatment: Black and Hispanic women particularly at risk. Genet Med. 2011;13(4):349–55.PubMedPubMedCentral
59.
Cragun D, Bonner D, Kim J, Akbari MR, Narod SA, Gomez-Fuego A, et al. Factors associated with genetic counseling and BRCA testing in a population-based sample of young Black women with breast cancer. Breast Cancer Res Treat. 2015;151(1):169–76.PubMedPubMedCentral
60.
Jagsi R, Griffith KA, Kurian AW, Morrow M, Hamilton AS, Graff JJ, et al. Concerns about cancer risk and experiences with genetic testing in a diverse population of patients with breast cancer. J Clin Oncol. 2015;33(14):1584–91.PubMedPubMedCentral
61.
McCarthy AM, Bristol M, Domchek SM, Groeneveld PW, Kim Y, Motanya UN, et al. Health care segregation, physician recommendation, and racial disparities in BRCA1/2 testing among women with breast cancer. J Clin Oncol. 2016;34:2610–8.PubMedPubMedCentral
62.
Randall TC, Armstrong K. Health care disparities in hereditary ovarian cancer: are we reaching the underserved population? Curr Treat Options in Oncol. 2016;17(8):39.
63.
Kaplan CP, Haas JS, Perez-Stable EJ, Gregorich SE, Somkin C, Des Jarlais G, et al. Breast cancer risk reduction options: awareness, discussion, and use among women from four ethnic groups. Cancer Epidemiol Biomarkers Prev. 2006;15(1):162–6.PubMed
64.
Adams I, Christopher J, Williams KP, Sheppard VB. What black women know and want to know about counseling and testing for BRCA1/2. J Cancer Educ. 2015;30(2):344–52.PubMedPubMedCentral
65.
Sheppard VB, Graves KD, Christopher J, Hurtado-de-Mendoza A, Talley C, Williams KP. African American women's limited knowledge and experiences with genetic counseling for hereditary breast cancer. J Genet Couns. 2014;23(3):311–22.PubMed
66.
Glenn BA, Chawla N, Bastani R. Barriers to genetic testing for breast cancer risk among ethnic minority women: an exploratory study. Ethn Dis. 2012;22(3):267–73.PubMed
67.
Hereditary Cancer Syndromes and Risk Assessment: ACOG COMMITTEE OPINION, Number 793. Obstet Gynecol. 2019;134(6):e143–e9.
68.
Robson ME, Bradbury AR, Arun B, Domchek SM, Ford JM, Hampel HL, et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for Cancer susceptibility. J Clin Oncol. 2015;33(31):3660–7.PubMed
69.
Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US preventive services task force recommendation statement. JAMA. 2019;322(7):652–65.PubMed
70.
71.
Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol. 1996;14(5):1730–6 discussion 7–40.
72.
Rubanovich CK, Cheung C, Mandel J, Bloss CS. Physician preparedness for big genomic data: a review of genomic medicine education initiatives in the United States. Hum Mol Genet. 2018;27(R2):R250–r8.PubMedPubMedCentral
73.
Cragun D, Camperlengo L, Robinson E, Caldwell M, Kim J, Phelan C, et al. Differences in BRCA counseling and testing practices based on ordering provider type. Genet Med. 2015;17(1):51–57
74.
Vadaparampil ST, Scherr CL, Cragun D, Malo TL, Pal T. Pre-test genetic counseling services for hereditary breast and ovarian cancer delivered by non-genetics professionals in the state of Florida. Clin Genet. 2015;87(5):473–477.
75.
Katz SJ, Ward KC, Hamilton AS, McLeod MC, Wallner LP, Morrow M, et al. Gaps in receipt of clinically indicated genetic counseling after diagnosis of breast cancer. J Clin Oncol. 2018;36(12):1218–24.PubMedPubMedCentral
76.
Whitworth P, Beitsch P, Arnell C, Cox HC, Brown K, Kidd J, et al. Impact of payer constraints on access to genetic testing. J Oncol Pract. 2017;13(1):e47–56.PubMed
77.
Stenehjem DD, Au T, Sainski AM, Bauer H, Brown K, Lancaster J, et al. Impact of a genetic counseling requirement prior to genetic testing. BMC Health Serv Res. 2018;18(1):165.PubMedPubMedCentral
78.
Watson M, Kash KM, Homewood J, Ebbs S, Murday V, Eeles R. Does genetic counseling have any impact on management of breast cancer risk? Genet Test. 2005;9(2):167–74.PubMed
79.
Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome. Nat Clin Pract Oncol. 2007;4(10):578–90.PubMed
80.
Narod SA, Offit K. Prevention and management of hereditary breast cancer. J Clin Oncol. 2005;23(8):1656–63.PubMed
81.
Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967–75.PubMedPubMedCentral
82.
Finch AP, Lubinski J, Moller P, Singer CF, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32(15):1547–53.PubMedPubMedCentral
83.
Maxwell KN, Domchek SM. Cancer treatment according to BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol. 2012;9(9):520–8.PubMed
84.
Tinoco G, Warsch S, Gluck S, Avancha K, Montero AJ. Treating breast cancer in the 21st century: emerging biological therapies. J Cancer. 2013;4(2):117–32.PubMedPubMedCentral
85.
Salhab M, Bismohun S, Mokbel K. Risk-reducing strategies for women carrying BRCA1/2 mutations with a focus on prophylactic surgery. BMC Womens Health. 2010;10:28.PubMedPubMedCentral
86.
Warner E. Screening BRCA1 and BRCA2 mutation carriers for breast cancer. Cancers (Basel). 2018;10(12):477.
87.
Carbine NE, Lostumbo L, Wallace J, Ko H. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst Rev. 2018;4(4):CD002748.PubMed
88.
Conley CC, Ketcher D, Reblin M, Kasting ML, Cragun D, Kim J, et al. The big reveal: family disclosure patterns of BRCA genetic test results among young Black women with invasive breast cancer. J Genet Couns. 2020. https://​doi.​org/​10.​1002/​jgc4.​1196.
90.
• Robson M, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New Engl J Med. 2017;377(6):523–33 This article highlights the first FDA approval of a PARP inhibitor for gBRCA metastaticHER2- breast cancer. PubMed
90.
Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee K-H, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753–63.PubMed
92.
•• Loree JM, Anand S, Dasari A, Unger JM, Gothwal A, Ellis LM, et al. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncol. 2019;5(10):e191870 This review highlights the suboptimal race reporting and representation of Blacks and Hispanics in landmark oncology trials.
Metadata
Title
Disparities in Genetic Testing and Care Among Black Women with Hereditary Breast Cancer
Authors
Sonya Reid
Sydney Cadiz
Tuya Pal
Publication date
01-09-2020
Publisher
Springer US
Published in
Current Breast Cancer Reports / Issue 3/2020
Print ISSN: 1943-4588
Electronic ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-020-00364-1

Other articles of this Issue 3/2020

Current Breast Cancer Reports 3/2020 Go to the issue

Lymphedema Incidence, Prevention and Treatment (J Armer, Section Editor)

Surgical Approaches to the Prevention and Management of Breast Cancer–Related Lymphedema

Breast Cancer Disparities (LA Newman, Section Editor)

The Role of Artificial Intelligence in Understanding and Addressing Disparities in Breast Cancer Outcomes

Lymphedema Incidence, Prevention and Treatment (J Armer, Section Editor)

Do Women with Breast Cancer–related Lymphoedema Need to Wear Compression While Exercising?: Results from a Systematic Review and Meta-analysis

Hot Topic

Return-to-Work and Breast Cancer Survivorship Care

Breast Cancer Disparities (LA Newman, Section Editor)

Impact of Genetic Ancestry on Treatment Toxicity and Racial Disparities in Breast Cancer

Breast Cancer Disparities (LA Newman, Section Editor)

Breast Reconstruction Disparities in the United States and Internationally
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits